Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XmAb22841 |
Synonyms | |
Therapy Description |
Pavunalimab (XmAb22841), is a bispecific antibody that targets CTLA4 and LAG3, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XmAb22841 | Pavunalimab | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 LAG3 Antibody 18 | Pavunalimab (XmAb22841), is a bispecific antibody that targets CTLA4 and LAG3, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |